- Meeting abstract
- Open Access
Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis
https://doi.org/10.1186/1758-5996-7-S1-A58
© Pinto et al. 2015
- Published: 11 November 2015
Keywords
- Placebo
- Systolic Blood Pressure
- Metformin
- Diastolic Blood Pressure
- Blood Pressure Reduction
Background
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are a novel antidiabetic class that inhibits glucose reabsorption and produce glycosuria. These medications are being increasingly used as dual therapy with metformin for type 2 diabetes (T2D) treatment, due to their beneficial effect on weight and blood pressure. Three agents are approved for clinical use and they may differ on potency due to inhibition of only renal or both renal and bowel glucose transportation.
Objective
to evaluate the efficacy of SGLT2i, dapagliflozin (DAPA), canagliflozin (CANA) and empagliflozin (EMPA), on HbA1c, weight and blood pressure (BP) in comparison with placebo and other antidiabetic medications.
Materials and methods
MEDLINE, Cochrane central and EMBASE databases were searched for randomized clinical trials (RCTs) including patients with T2D allocated to SGLT2i for at least 12 weeks. A direct and network meta-analysis (NMA) were conducted.
Results
Effects of SGLT2i on HbA1c (A) and weight reducAon (B) compared to other antidiabetic medications
Conclusion
In T2D patients, SGLT2i were superior to placebo for all outcomes analyzed, and CANA seems to be the most potent among then. SGLT2i are as effective as metformin and sulphonylurea and superior to DPP4 inhibitors for HbA1c, but more potent than these classes regarding weight and BP reduction.
Authors’ Affiliations
Copyright
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.